Hyperfine (HYPR) & The Competition Head to Head Review

Hyperfine (NASDAQ:HYPR) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its rivals? We will compare Hyperfine to related businesses based on the strength of its dividends, risk, valuation, institutional ownership, earnings, profitability and analyst recommendations.

Insider and Institutional Ownership

15.0% of Hyperfine shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 26.3% of Hyperfine shares are held by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Hyperfine and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1	1	3	1	2.67
Hyperfine Competitors	4290	10574	18359	830	2.46

Hyperfine presently has a consensus target price of $2.02, indicating a potential upside of 184.69%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 20.54%. Given Hyperfine’s stronger consensus rating and higher possible upside, research analysts plainly believe Hyperfine is more favorable than its rivals.

Profitability

This table compares Hyperfine and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hyperfine	-156.42%	-91.18%	-55.49%
Hyperfine Competitors	-304.20%	-315.07%	-22.11%

Volatility & Risk

Hyperfine has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Comparatively, Hyperfine’s rivals have a beta of 2.57, meaning that their average stock price is 157% more volatile than the S&P 500.

Earnings & Valuation

This table compares Hyperfine and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Hyperfine	$11.40 million	-$35.57 million	-1.87
Hyperfine Competitors	$1.89 billion	$136.81 million	5.75

Hyperfine’s rivals have higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Hyperfine rivals beat Hyperfine on 7 of the 13 factors compared.

Hyperfine Company Profile

Hyperfine, Inc. (NASDAQ: HYPR) is a medical technology company focused on making magnetic resonance imaging more accessible and convenient. The company develops portable, low-field MRI technology designed to bring brain imaging directly to patients in locations such as intensive care units, emergency departments, operating rooms and other point-of-care settings. Hyperfine’s primary product is the Swoop Portable MR Imaging System, a compact MRI platform that can be moved to a patient’s bedside. The system is designed to produce brain images without requiring patients to be transported to a traditional radiology department.